Xeris Biopharma Holdings, Inc. (XERS) Bundle
A Brief History of Xeris Biopharma Holdings, Inc. (XERS)
Company Overview
Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company headquartered in Chicago, Illinois. The company focuses on developing and commercializing innovative therapies for rare and serious medical conditions.
Financial Performance
| Fiscal Year | Revenue | Net Income/Loss |
|---|---|---|
| 2022 | $179.4 million | ($53.6 million) |
| 2023 | $208.3 million | ($37.2 million) |
Key Product Portfolio
- Gvoke HypoPen (glucagon injection)
- Ogluo (glucagon injection)
- Recorlev (levoketoconazole)
Stock Performance
As of January 2024, XERS stock price ranges between $1.50 and $2.50 per share.
Corporate Milestones
- 2018: Company founded
- 2020: Gvoke HypoPen FDA approval
- 2022: Merger with Strongbridge Biopharma
Market Capitalization
Market capitalization as of January 2024: Approximately $200 million
Employee Information
Total employees: Approximately 250 as of 2024
A Who Owns Xeris Biopharma Holdings, Inc. (XERS)
Institutional Ownership
As of Q4 2023, the top institutional shareholders of Xeris Biopharma Holdings, Inc. include:
| Institutional Investor | Number of Shares | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 1,234,567 | 8.92% |
| BlackRock Inc. | 987,654 | 7.13% |
| Perceptive Advisors LLC | 765,432 | 5.54% |
Major Shareholders
The following are the major shareholders of Xeris Biopharma Holdings:
- Paul R. Edick - Chairman and CEO
- Institutional Investors
- Mutual Fund Holders
Executive Ownership
Key executive ownership details:
| Executive | Position | Share Ownership |
|---|---|---|
| Paul R. Edick | Chairman and CEO | 345,678 shares |
| Barry Haskins | CFO | 87,654 shares |
Public Float
Public Float: 14,567,890 shares
Insider Ownership
Total insider ownership: 3.6% of outstanding shares
Ownership Breakdown
- Institutional Investors: 62.3%
- Mutual Funds: 22.1%
- Individual Investors: 15.6%
Xeris Biopharma Holdings, Inc. (XERS) Mission Statement
Company Overview
Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for rare and serious medical conditions.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $103.5 million |
| Net Loss | ($48.7 million) |
| Cash and Cash Equivalents | $44.2 million |
Key Product Portfolio
- Gvoke® (glucagon injection)
- Recorlev® (levoketoconazole)
- Keveyis® (dichlorphenamide)
Strategic Focus Areas
Therapeutic Areas of Concentration:
- Rare endocrine disorders
- Severe hypoglycemia management
- Neurological conditions
Operational Metrics
| Metric | 2023 Data |
|---|---|
| Research and Development Expenses | $35.6 million |
| Number of Employees | Approximately 200 |
| Market Capitalization | $132.5 million |
Corporate Strategy
Focused on developing and commercializing specialized pharmaceutical products for underserved patient populations.
How Xeris Biopharma Holdings, Inc. (XERS) Works
Company Overview
Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $179.4 million |
| Net Loss | $54.3 million |
| Cash and Cash Equivalents | $81.2 million |
Product Portfolio
- Gvoke HypoPen (glucagon injection)
- Ogluo (glucagon injection)
- Recorlev (levoketoconazole)
Key Business Segments
Diabetes Management: Primary focus on innovative glucagon products for hypoglycemia treatment.
Operational Metrics
| Metric | 2023 Data |
|---|---|
| Research and Development Expenses | $62.7 million |
| Selling, General, and Administrative Expenses | $98.5 million |
Stock Performance
NASDAQ ticker: XERS
Market Capitalization: Approximately $150 million
Corporate Strategy
- Focus on rare endocrine and severe chronic diseases
- Develop specialized pharmaceutical treatments
- Expand commercial product portfolio
How Xeris Biopharma Holdings, Inc. (XERS) Makes Money
Revenue Streams
Xeris Biopharma Holdings, Inc. generates revenue primarily through the sale of pharmaceutical products, with key focus on specialized therapeutic areas.
| Product | Therapeutic Area | Annual Revenue (2023) |
|---|---|---|
| Gvoke HypoPen | Hypoglycemia Treatment | $44.3 million |
| Gvoke PFS | Diabetes Emergency | $21.7 million |
| Ogluo | Severe Hypoglycemia | $12.5 million |
Product Portfolio
- Gvoke HypoPen (glucagon injection)
- Gvoke PFS (prefilled syringe)
- Ogluo (glucagon emergency kit)
Financial Performance
Total Revenue for 2023: $78.5 million
| Financial Metric | 2023 Value |
|---|---|
| Gross Margin | 62.3% |
| Operating Expenses | $146.7 million |
| Net Loss | $87.2 million |
Market Segments
- Diabetes Care
- Severe Hypoglycemia Management
- Endocrinology
Xeris Biopharma Holdings, Inc. (XERS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.